Related Experiment Videos
Sulindac suppresses tumorigenesis in the Min mouse
Y Beazer-Barclay1, D B Levy, A R Moser
1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Carcinogenesis
|August 1, 1996
Summary
Sulindac significantly reduced colorectal tumors in Min mice, a model for human cancer. This validates the Min mouse model for testing new cancer prevention drugs.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- The Min mouse is a genetic model for human colorectal cancer.
- Sulindac is known to inhibit colorectal tumorigenesis in humans.
Purpose of the Study:
- To evaluate the Min mouse model for testing chemopreventive agents.
- To assess the efficacy of sulindac in the Min mouse model.
Main Methods:
- Min mice were treated with sulindac via drinking water or diet.
- Tumor load was measured to assess the drug's effect.
Main Results:
- Sulindac treatment significantly decreased the average tumor load in Min mice.
- The results demonstrate sulindac's chemopreventive activity in this model.
Conclusions:
- The Min mouse model is suitable for evaluating chemopreventive agents like sulindac.
- This model can be used to study sulindac's mechanism and test other agents.